Acerus Pharmaceuticals Corporation (TSX:ASP) today reported its financial results for the three and twelve-month period ended December 31, 2016. Unless otherwise noted, all amounts are in U.S. dollars.
"Despite the introduction of an Estrace® generic, Acerus managed to deliver strong financial results for the year and significantly strengthened its balance sheet," said Tom Rossi, President and Chief Executive Officer. "We are very excited about the new Natesto® partners we have brought o
RelSci News & Alerts gets you: